Edgewise Therapeutics Inc (EWTX)
17.13
-0.37
(-2.11%)
USD |
NASDAQ |
May 31, 16:00
17.14
+0.01
(+0.06%)
After-Hours: 20:00
Edgewise Therapeutics Research and Development Expense (Quarterly): 27.69M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 27.69M |
| December 31, 2023 | 27.68M |
| September 30, 2023 | 23.79M |
| June 30, 2023 | 19.56M |
| March 31, 2023 | 19.88M |
| December 31, 2022 | 16.61M |
| September 30, 2022 | 13.89M |
| June 30, 2022 | 12.40M |
| March 31, 2022 | 11.12M |
| Date | Value |
|---|---|
| December 31, 2021 | 9.088M |
| September 30, 2021 | 9.88M |
| June 30, 2021 | 7.861M |
| March 31, 2021 | 5.36M |
| December 31, 2020 | 5.139M |
| September 30, 2020 | 3.238M |
| June 30, 2020 | 3.639M |
| March 31, 2020 | 2.967M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.967M
Minimum
Mar 2020
27.69M
Maximum
Mar 2024
12.93M
Average
11.12M
Median
Mar 2022
Research and Development Expense (Quarterly) Benchmarks
| Pfizer Inc | 2.493B |
| Sarepta Therapeutics Inc | 200.40M |
| PTC Therapeutics Inc | 116.13M |
| Regenxbio Inc | 54.84M |
| Alnylam Pharmaceuticals Inc | 261.00M |